In the randomized phase 2 study CITYSCAPE, we evaluated the efficacy of first-line tiragolumab plus atezolizumab versus atezolizumab monotherapy in patients with PD-L1-positive (tumour proportion score (TPS) ≥ 1%) NSCLC. The gene discussed is CD274; the disease is neoplasm.